Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Publicly Funded R&D In EU Should Come With Conditions, Says Report

Executive Summary

Conditions should be attached to the public funding of biomedical R&D in response to escalating prices of drugs developed with public money, a new report says.

You may also be interested in...



Countries Urged To Open Up On Managed Entry Deals

Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.

The Netherlands Swaps Germany For Norway To Set Prices

The Netherlands will secure lower medicine prices by referencing Norway instead of Germany to set maximum prices. 

Luxembourg To Establish New Medicines Agency

Luxembourg’s new regulator will work to attract investment and improve public health as well as tackle the growing problem of drug shortages.

Topics

UsernamePublicRestriction

Register

PS125336

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel